Nurse Practitioner, Family · Duarte, CA
NPI
1295176394
Since 2013
Specialty
Nurse Practitioner, Family
Code 363LF0000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1500 E Duarte Rd
Duarte, CA, 91010
Phone (626) 256-4673
Groups this clinician bills Medicare through
Medicare paid, 2024
$31K
427 services
Medicare patients, 2024
134
Average age 72
Drug cost, 2024
$6.9M
1,310 prescriptions
Company payments, 2025
$67.44
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Razmig V Babikian was code 99214 (office e&m - established), 217 times for 90 patients. In total Razmig V Babikian billed 427 services in 13 codes, and Medicare paid $31K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-11-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 217 | 90 | $70.75 | $15K |
| 99215 Office E&M - Established | Facility | 67 | 50 | $103.97 | $6,966 |
| 99214 Office E&M - Established | Office | 41 | 25 | $88.89 | $3,644 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 26 | 22 | $12.09 | $314 |
| 99213 Office E&M - Established | Facility | 21 | 17 | $48.19 | $1,012 |
| 99213 Office E&M - Established | Office | 14 | 11 | $58.55 | $820 |
By year: 2022 $24K for 311 services; 2023 $32K for 435 services; 2024 $31K for 427 services.
Medicare prescription drug claims, 2024
In 2024, the drug Razmig V Babikian prescribed most often to Medicare patients was Tagrisso (Osimertinib Mesylate), with 270 prescriptions and refills. In total Razmig V Babikian wrote 1,310 Medicare prescriptions that cost $6.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tagrisso Osimertinib Mesylate | 270 | 272 | 33 | $4.4M |
| Eliquis Apixaban | 73 | 86 | 19 | $49K |
| Pantoprazole Sodium Generic | 65 | 93 | 20 | $525 |
| Gilotrif Afatinib Dimaleate | 47 | 47 | Under 11 | $513K |
| Dexamethasone Generic | 47 | 58 | 26 | $763 |
| Gabapentin Generic | 36 | 44 | Under 11 | $311 |
| Prednisone Generic | 31 | 46 | 18 | $222 |
| Ondansetron Hcl Generic | 31 | 31 | 23 | $291 |
| Prochlorperazine Maleate Generic | 29 | 29 | 21 | $293 |
| Azithromycin Generic | 26 | 26 | 20 | $111 |
| Tepmetko Tepotinib Hcl | 26 | 26 | Under 11 | $624K |
| Entecavir Generic | 23 | 31 | Under 11 | $910 |
| Alecensa Alectinib Hcl | 23 | 23 | Under 11 | $411K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 22 | 35 | 11 | $182 |
| Nystatin Generic | 22 | 22 | 11 | $520 |
Brand drugs: - claims; generic drugs: 723 claims; opioid claims: 26.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Razmig V Babikian $67.44 ($67.44 in general payments such as food, travel and fees) from 2 companies. The largest payer was Pfizer Inc. with $38.01.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.